source
- Karyopharm stock tumbles after Phase 3 Xpovio trial fails in endometrial cancerKaryopharm announced that its Phase 3 XPORT-EC-042 study of Xpovio in endometrial cancer did not meet its primary endpoint. The failure represents the company's second unsuccessful attempt to expa…
- Catheter Introducer Kit Recall: Abiomed Removes 14Fr Low Profile Introducer KitsProlonged use of the Abiomed 14Fr Low Profile Introducer may lead to thrombus formation.fda medwatch · 16h ago↗ source